Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/4094
Title: | The E2F-regulated gene Chk1 is highly expressed in triple-negative estrogen receptor-/progesterone receptor-/HER-2- Breast carcinomas | Authors: | Verlinden, Lieve Vanden Bempt, Isabelle Eelen, Guy Drijkoningen, Maria VERLINDEN, Ilse Marchal, Kathleen De Wolf-Peeters, Christiane Christiaens, Marie-Rose MICHIELS, Luc Bouillon, Roger Verstuyf, Annernieke |
Issue Date: | 2007 | Publisher: | AMER ASSOC CANCER RESEARCH | Source: | CANCER RESEARCH, 67(14). p. 6574-6581 | Abstract: | We previously showed that checkpoint kinase 1 (Chk1) and Claspin, two DNA-damage checkpoint proteins, were down-regulated by 1,25-dihydroxyvitamin D-3, a known inhibitor of cell proliferation. In the present study, we aimed to investigate the transcriptional regulation of Chk1 and Claspin and to study their expression levels in human breast cancer tissue. Transient transfection experiments in MCF-7 breast cancer cells showed that promoter activities of Chk1 and Claspin were regulated by the E2F family of transcription factors. Subsequently, transcript levels of Chk1, Claspin, and E2F1 were determined by quantitative reverse transcriptase-PCR analysis in 103 primary invasive breast carcinomas and were compared with several clinicopathologic variables in breast cancer. A strong correlation was found between Chk1 and Claspin transcript levels. Transcript levels of Chk1, Claspin, and E2F] were highest in histologic grade 3 tumors and in tumors in which the expression of estrogen receptor (ER) and progesterone receptor (PR) was lost. Moreover, Chk1 expression was significantly elevated in grade 3 breast carcinomas showing a triple-negative ER-/PR-/HER-2- phenotype compared with other grade 3 tumors. Further research is warranted to validate the use of Chk1 inhibitors in triple-negative breast carcinomas for which treatment strategies are limited at present. | Notes: | Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, B-3000 Louvain, Belgium. Katholieke Univ Leuven, CMPG ESAT, Louvain, Belgium. Katholieke Univ Leuven, Univ Hosp, Dept Pathol, Louvain, Belgium. Katholieke Univ Leuven, Univ Hosp, Multidisciplinary Breast Ctr, Louvain, Belgium. Katholieke Univ Leuven, Univ Hosp, Dept Surg, Louvain, Belgium. Univ Hasselt, Biomed Res Inst BIOMED, Diepenbeek, Belgium.Verstuyf, A, Katholieke Univ Leuven, Lab Expt Geneeskunde & Endocrinol, Legendo,Bus 902,Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.Mieke.Verstuyf@med.kuleuven.be | Document URI: | http://hdl.handle.net/1942/4094 | ISSN: | 0008-5472 | e-ISSN: | 1538-7445 | DOI: | 10.1158/0008-5472.CAN-06-3545 | ISI #: | 000248319000008 | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2008 |
Appears in Collections: | Research publications |
Show full item record
SCOPUSTM
Citations
105
checked on Sep 2, 2020
WEB OF SCIENCETM
Citations
129
checked on Oct 14, 2024
Page view(s)
68
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.